Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guang-Yu Liu

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Breast (Edinburgh, Scotland)|February 13, 2007
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patientsKe-Da Yu, Guang-Yu Liu, Gen-Hong Di, et al.
Annals of Translational Medicine|April 21, 2023
Neoadjuvant <i>Pseudomonas aeruginosa</i> mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trialYue Gong, Hua Zuo, Ying Zhou, et al.
Chinese Journal of Integrative Medicine|March 18, 2015
L-tetrahydropalamatine inhibits tumor necrosis factor-α-induced monocyte-endothelial cell adhesion through downregulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 involving suppression of nuclear factor-κ B signaling pathwayBin-rui Yang, Nan Yu, Yan-hui Deng, et al.
Journal of Cancer Research and Clinical Oncology|May 20, 2008
Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatmentKe-da Yu, Gen-hong Di, Jiong Wu, et al.
Cell Death and Differentiation|January 2, 2022
O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progressionYing-Ying Liu, Hong-Yi Liu, Tian-Jian Yu, et al.
Biophysical Journal|August 19, 2009
Structural characterization of edematous corneas by forward and backward second harmonic generation imagingChiu-Mei Hsueh, Wen Lo, Wei-Liang Chen, et al.
The Oncologist|May 3, 2013
Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks scheduleKe-Da Yu, Guang-Yu Liu, Can-Ming Chen, et al.
Plos One|April 16, 2015
Surgical management for early-stage bilateral breast cancer patients in ChinaJia-jian Chen, Nai-si Huang, Jing-yan Xue, et al.
Molecular Medicine Reports|September 6, 2019
Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor‑κB signaling pathwayLiu Yang, Qi Hong, Si-Guang Xu, et al.
Breast Cancer Research and Treatment|January 21, 2009
Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, ChinaLei Fan, Ying Zheng, Ke-Da Yu, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Breast (Edinburgh, Scotland)|February 13, 2007
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patientsKe-Da Yu, Guang-Yu Liu, Gen-Hong Di, et al.
Annals of Translational Medicine|April 21, 2023
Neoadjuvant <i>Pseudomonas aeruginosa</i> mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trialYue Gong, Hua Zuo, Ying Zhou, et al.
Chinese Journal of Integrative Medicine|March 18, 2015
L-tetrahydropalamatine inhibits tumor necrosis factor-α-induced monocyte-endothelial cell adhesion through downregulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 involving suppression of nuclear factor-κ B signaling pathwayBin-rui Yang, Nan Yu, Yan-hui Deng, et al.
Journal of Cancer Research and Clinical Oncology|May 20, 2008
Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatmentKe-da Yu, Gen-hong Di, Jiong Wu, et al.
Cell Death and Differentiation|January 2, 2022
O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progressionYing-Ying Liu, Hong-Yi Liu, Tian-Jian Yu, et al.
Biophysical Journal|August 19, 2009
Structural characterization of edematous corneas by forward and backward second harmonic generation imagingChiu-Mei Hsueh, Wen Lo, Wei-Liang Chen, et al.
The Oncologist|May 3, 2013
Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks scheduleKe-Da Yu, Guang-Yu Liu, Can-Ming Chen, et al.
Plos One|April 16, 2015
Surgical management for early-stage bilateral breast cancer patients in ChinaJia-jian Chen, Nai-si Huang, Jing-yan Xue, et al.
Molecular Medicine Reports|September 6, 2019
Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor‑κB signaling pathwayLiu Yang, Qi Hong, Si-Guang Xu, et al.
Breast Cancer Research and Treatment|January 21, 2009
Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, ChinaLei Fan, Ying Zheng, Ke-Da Yu, et al.
Pageof 12